抑郁癥是嚴(yán)重危害人類身心健康的常見病，隨著"生物-心理-社會"的現(xiàn)代醫(yī)學(xué)模式轉(zhuǎn)變，發(fā)現(xiàn)其常與其他重大疾病如糖尿病、高血脂、心臟病、高血壓等代謝綜合征組分并存，合并疾病發(fā)病率高且預(yù)后不良，以及造成對家庭和社會的高負(fù)擔(dān)，關(guān)于其發(fā)病機(jī)制和防治措施的研究方興未艾。抑郁癥和代謝性疾病的發(fā)病可能存在一定共病基礎(chǔ)和因果關(guān)系，旨在重點(diǎn)探討脂質(zhì)代謝紊亂和血管內(nèi)皮功能障礙在抑郁癥合并代謝性疾病的病理發(fā)展和共病機(jī)制中的作用，同時(shí)歸納總結(jié)現(xiàn)有治療藥物對脂質(zhì)代謝異常和內(nèi)皮功能障礙的影響，為臨床用藥的優(yōu)選及其共病患者的治療方式提供綜述基礎(chǔ)。

Depression is a common disease that seriously endangers the physical and mental health of human beings with the change of the "bio-psycho-social" modern medical model, and it is found that depression often coexists with other major diseases such as diabetes, hyperlipidemia, heart disease, hypertension, and other metabolic syndrome components. The research on its pathogenesis and prevention measures is in the ascendant because of its high incidence and poor prognosis, as well as the high burden on the family and society. There may be a certain co-morbid basis and causal relationship between depression and metabolic diseases. The purpose of this paper is to explore the role of lipid metabolism disorder and vascular endothelial dysfunction in the pathological development and co-morbid mechanism of depression complicated with metabolic diseases. At the same time, the effects of existing therapeutic drugs on abnormal lipid metabolism and endothelial dysfunction are summarized. The purpose of this study is to provide a summary basis for the optimization of clinical medication and the treatment of patients with co-morbidities.

R971

國家自然科學(xué)基金資助項(xiàng)目（81973520）